Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.

Bilic I, Zoricic I, Anic T, Separovic J, Stancic-Rokotov D, Mikus D, Buljat G, Ivankovic D, Aralica G, Prkacin I, Perovic D, Mise S and 5 more

Show all authors

Rotkvic I, Petek M, Rucman R, Seiwerth S, Sikiric P

Life sciences1 Mar 2001Cited by 21 (Europe PMC)

PMID11292068DOI10.1016/s0024-3205(00)01025-0PepBankPUB-11292068

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In haloperidol-challenged mice, BPC‑157 inhibited stomach lesions at the 10 µg, 10 ng and 10 pg doses.
In plain wordsIn mice given haloperidol, BPC‑157 reduced stomach lesions at the three higher doses tested.
Peptide
BPC-157
Outcome
DecreaseHaloperidol stomach lesions (effective doses)
Study
mousen: not reported in source
haloperidol-induced stomach lesions
Comparator
Haloperidol plus saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 µg, 10 ng or 10 pg/kg · intraperitonealAs given in this study (mouse).
Measurements
effective dose
10 µg
BPC 157
effective dose
10 ng
BPC 157
effective dose
10 pg
BPC 157
Source sentences
Summary
In haloperidol+saline challenged mice the lesions were inhibited by co-administration (/kg i.p.) of a gastric pentadecapeptide BPC 157, GlyGluProProProGlyLysProAlaAspAspAlaGlyLeuVal, M.W. 1419 (10 microg, 10 ng, 10 pg, but not 1 pg, 100 fg, 10 fg)
1 context sentence(design, population, supporting numbers)
Summary · context
Male NMRI Hannnover mice were sacrificed 24 h after haloperidol (25 mg/kg b.w. i.p., given alone or with saline (haloperidol+saline) (i) or in combination (ii,iii)).
Report a problemFND-1129206801
02AnimalAnimal study (in vivo)Efficacy outcome
In haloperidol-challenged mice, BPC‑157 at 1 pg, 100 fg and 10 fg did not inhibit stomach lesions.
In plain wordsIn mice given haloperidol, BPC‑157 did not reduce stomach lesions at the three lowest doses tested.
Peptide
BPC-157
Outcome
No significant changeHaloperidol stomach lesions (ineffective doses)
Study
mousen: not reported in source
haloperidol-induced stomach lesions
Comparator
Haloperidol plus saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
1 pg, 100 fg or 10 fg/kg · intraperitonealAs given in this study (mouse).
Measurements
ineffective dose
1 pg
BPC 157
ineffective dose
100 fg
BPC 157
ineffective dose
10 fg
BPC 157
Source sentences
Summary
In haloperidol+saline challenged mice the lesions were inhibited by co-administration (/kg i.p.) of a gastric pentadecapeptide BPC 157, GlyGluProProProGlyLysProAlaAspAspAlaGlyLeuVal, M.W. 1419 (10 microg, 10 ng, 10 pg, but not 1 pg, 100 fg, 10 fg)
1 context sentence(design, population, supporting numbers)
Summary · context
Male NMRI Hannnover mice were sacrificed 24 h after haloperidol (25 mg/kg b.w. i.p., given alone or with saline (haloperidol+saline) (i) or in combination (ii,iii)).
Report a problemFND-1129206802
03AnimalAnimal study (in vivo)Mechanism
In mice given haloperidol with domperidone, BPC‑157 did not attenuate stomach lesions.
In plain wordsIn mice given haloperidol and a peripheral dopamine blocker, BPC‑157 did not reduce stomach lesions.
Peptide
BPC-157
Outcome
No significant changeHaloperidol stomach lesions with peripheral dopamine blockade
Study
mousen: not reported in source
haloperidol-induced stomach lesions
Comparator
Haloperidol plus domperidone
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 µg/kg · intraperitonealAs given in this study (mouse).
Source sentences
Summary
in haloperidol+domperidone mice, previously effective bromocriptine, pentadecapeptide BPC 157 (10 microg) or omeprazole (10 mg) did not attenuate stomach lesions
1 context sentence(design, population, supporting numbers)
Summary · context
Male NMRI Hannnover mice were sacrificed 24 h after haloperidol (25 mg/kg b.w. i.p., given alone or with saline (haloperidol+saline) (i) or in combination (ii,iii)).
Report a problemFND-1129206803
04AnimalAnimal study (in vivo)Mechanism
In mice given haloperidol with indomethacin, the BPC‑157 effect on stomach lesions was only lessened, not abolished.
In plain wordsIn mice given haloperidol and indomethacin, the protective effect of BPC‑157 on the stomach was reduced but not lost.
Peptide
BPC-157
Outcome
MixedHaloperidol stomach lesions with prostaglandin synthesis blockade
Study
mousen: not reported in source
haloperidol-induced stomach lesions
Comparator
Haloperidol plus indomethacin
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study (mouse).
Source sentences
Summary
in haloperidol+indomethacin mice, previously effective agents, bromocriptine or omeprazole were not active, while BPC 157 effect was only lessened
1 context sentence(design, population, supporting numbers)
Summary · context
Male NMRI Hannnover mice were sacrificed 24 h after haloperidol (25 mg/kg b.w. i.p., given alone or with saline (haloperidol+saline) (i) or in combination (ii,iii)).
Report a problemFND-1129206804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.